Shares of Lantheus (LNTH) are up $8.35, or 12% to $76.00 in pre-market trading after Eli Lilly (LLY) announced a definitive agreement to acquire Point Biopharma (PNT) for a purchase price of $12.50 per share in cash payable at closing. Lantheus holds a worldwide license for Point’s 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LNTH:
- Lantheus initiated with an Outperform at William Blair
- Lantheus price target lowered to $110 from $125 at Truist
- Truist med tech/biotech analysts hold analyst/industry conference call
- Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting